Haemonetics (HAE) vs iRhythm (IRTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Haemonetics (HAE) has outperformed iRhythm (IRTC) over the past year, gaining 106.5% versus a loss of 40.9%. Over five years, HAE leads with a +45.5% price change compared with +45.2% for IRTC. Haemonetics is the larger company by market cap ($5.44 billion vs $3.38 billion), about 1.6 times the size, while iRhythm is growing revenue faster (+26.2% vs -2.0%).
On valuation, Haemonetics trades at a lower forward P/E (20.7x vs 80.1x for iRhythm). Haemonetics converts more of its revenue into profit, with a net margin of 7.3% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | IRTC |
|---|---|---|
| Share price | $119.47 | $102.60 |
| Market cap | $5.44B | $3.38B |
| 1-day change | +17.46% | -2.28% |
| YTD return | +26.90% | -40.83% |
| 1-year return | +106.48% | -40.89% |
| 5-year return | +45.49% | +45.23% |
| P/E ratio (TTM) | 57.71 | — |
| Forward P/E | 20.68 | 80.06 |
| EPS (TTM) | $2.07 | $-0.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | $747.14M |
| Revenue growth (YoY) | -1.97% | +26.24% |
| Net income (latest FY) | $97.31M | $-44.55M |
| Gross margin | 59.04% | 70.57% |
| Operating margin | 11.75% | -7.68% |
| Net margin | 7.29% | -5.96% |
| 52-week high | $120.72 | $212.00 |
| 52-week low | $48.17 | $100.70 |
| Distance from 52-week high | -1.04% | -51.60% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -6.67% | +69.52% |
| Average volume | 678.94K | 568.52K |
| Shares outstanding | 45.50M | 32.96M |
| Employees | 3,009 | 2,400 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed IRTC by 147.4 percentage points over the past year.
- Haemonetics is more profitable, keeping 7.3 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs -1.97%).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
HAE vs IRTC FAQ
Which is bigger, Haemonetics or iRhythm?
Haemonetics (HAE) is larger, with a market capitalization of $5.44B compared with $3.38B for iRhythm (IRTC).
Which stock has performed better over the past year, HAE or IRTC?
HAE returned +106.48% over the past 12 months, compared with -40.89% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are Haemonetics and iRhythm in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.